Gain Therapeutics, Inc. (GANX) SEC Filings — 2024
17 SEC filings for Gain Therapeutics, Inc. (GANX) in 2024.
Filings
- Gain Therapeutics Files 8-K — 8-K · Dec 23, 2024
- Gain Therapeutics Reports Q3 2024 Results — 10-Q · Nov 14, 2024
- Gain Therapeutics Files 8-K — 8-K · Oct 21, 2024
- Gain Therapeutics Files 8-K — 8-K · Oct 8, 2024
- Gain Therapeutics Files 8-K for Material Agreement — 8-K · Sep 6, 2024
- Gain Therapeutics Files 10-Q with $25.17M Interest Income — 10-Q · Aug 8, 2024
- Gain Therapeutics to be Delisted from Nasdaq — 8-K · Jul 12, 2024
- Gain Therapeutics Files 8-K — 8-K · Jul 9, 2024
- Gain Therapeutics Appoints New CMO, CSO, and Director — 8-K · Jun 28, 2024
- Gain Therapeutics Files 8-K on Shareholder Vote — 8-K · Jun 25, 2024
- Gain Therapeutics Enters Material Definitive Agreement — 8-K · Jun 14, 2024
- Gain Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 14, 2024
- Gain Therapeutics, Inc. Announces 2024 Annual Meeting of Stockholders — DEF 14A · Apr 26, 2024
- Gain Therapeutics Appoints New CMO and CSO, O'Connell Departs — 8-K · Apr 8, 2024
- Gain Therapeutics, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 26, 2024
- Gain Therapeutics Files 8-K on Officer/Director Changes — 8-K · Feb 22, 2024
- Gain Therapeutics Files 8-K, Confirms Emerging Growth Status — 8-K · Jan 31, 2024